Takeda Canada Awarded Tender for TAKHZYRO

2022-05-11T07:55:49-06:00

Héma-Québec, the organization in Quebec that manages blood and biological products, has awarded a two-year tender for TAKHZYRO® (lanadelumab injection), as the sole option for prophylaxis subcutaneous (SC) treatment for Type I/II HAE patients.